Study of nanvuranlat for advanced bile duct cancer
Part of Cancer, Digestive system clinical trials.
This study tests a new drug called nanvuranlat for people with advanced bile duct cancer that has gotten worse after platinum-based chemotherapy. It compares nanvuranlat with the doctor's choice of standard treatments to see which works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have bile duct cancer that has spread or cannot be removed by surgery.
- You have had at least one round of platinum-based chemotherapy for advanced disease, and it stopped working or you couldn't tolerate it.
- You are in good enough health to be up and around (ECOG performance status 0 or 1).
- You have at least one tumor that can be measured on a scan.
- You agree to testing for a protein called LAT1 on your tumor and genetic testing (NAT2 and transporter genes).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new form of chemotherapy (liposomal irinotecan, given with other drugs) for people whose bile duct, gallbladder, or other biliary cancer has advanced after first-line treatment. The goal is to see if this second-line combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of two drugs, sacituzumab tirumotecan and pembrolizumab, for people with advanced bile duct or gallbladder cancer that has grown after previous treatment. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests a combination of a targeted therapy (surufatinib), chemotherapy (gemcitabine and cisplatin), and an immunotherapy (durvalumab or pembrolizumab) for people with advanced bile duct cancer that hasn't been treated with systemic therapy before. The goal is to see if this combination can shrink tumors and improve outcomes.
This study tests a combination of freezing the tumor (cryoablation), an investigational immunotherapy (QL1706), and a targeted therapy pill (lenvatinib) for people with advanced bile duct cancer that has progressed after initial treatment. The goal is to see if this new combination can help control the cancer and improve outcomes.
This trial tests a new combination of an oncolytic virus plus lenvatinib and toripalimab (immunotherapy drugs) compared with the standard chemotherapy FOLFOX for advanced bile duct or gallbladder cancer. The goal is to see if the new combination helps people whose cancer has progressed after one line of treatment.
This trial tests whether giving a targeted medicine based on your tumor's genetic makeup, after surgery, can help prevent your bile duct or gallbladder cancer from coming back. It's a new approach that tries to match treatment to your specific cancer biology.
Hear when a new Advanced Biliary Tract Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.